The Ocular Hypertension Treatment Study - Topical medication delays or prevents primary open-angle glaucoma in African American individuals
The Ocular Hypertension Treatment Study - Topical medication delays or prevents primary open-angle glaucoma in African American individuals
复制标题
DOI：
10.1001/archopht.122.6.813
复制
发表时间：
2004-06-01
影响因子：
--
通讯作者：
Kass, MA
中科院分区：
文献类型：
--
作者：
Higginbotham, EJ;Gordon, MO;Kass, MA
背景资料：青光眼的患病率在非洲裔美国人中高于白色individual.Objective：报道局部眼内扩张药物在高眼压治疗研究中非洲裔美国人参与者中延迟或预防原发性开角型青光眼（POAG）发作的安全性和有效性。合格标准包括年龄在40至80岁之间，一只眼的眼内压在24至32 mm Hg之间，另一只眼的眼内压在21至32 mm Hg之间，并且通过标准临床测量没有昏迷性结构或功能损伤的证据。参与者被随机分配到观察组或药物组。在随机分配的1636名参与者中，408名自认为是非洲裔美国人。主要结果测量：主要结果是POAG引起的可再现视野异常和/或可再现视盘恶化的发展。在非洲裔美国人中，17药物治疗组203例患者中有8.4%在研究期间发生POAG（中位随访时间：78个月），（16.1%）观察组205名参与者（风险比，0.50; 95%置信区间，0.28-0.90; P= 0.02）。在患有高眼压症的非裔美国人中，局部眼部扩张治疗可有效延迟或预防POAG的发作。
Background: The prevalence of glaucoma is higher in African American individuals than in white individuals.Objective: To report the safety and efficacy of topical ocular hypotensive medication in delaying or preventing the onset of primary open-angle glaucoma (POAG) among African American participants in the Ocular Hypertension Treatment Study.Methods: Eligibility criteria included age between 40 and 80 years, intraocular pressure between 24 and 32 mm Hg in one eye and between 21 and 32 mm Hg in the other eye, and no evidence of glaucomatous structural or functional damage by standard clinical measures. Participants were randomized to either the observation group or medication group. Of the 1636 participants randomized, 408 were self-identified as African American.Main Outcome Measure: The primary outcome was the development of reproducible visual field abnormality and/or reproducible optic disc deterioration attributed to POAG.Results: Among African American participants, 17 (8.4%) of 203 in the medication group developed POAG during the study (median follow-up, 78 months) compared with 33 (16.1%) of 205 participants in the observation group (hazard ratio, 0.50; 95% confidence interval, 0.28-0.90; P=.02).Conclusion: Topical ocular hypotensive therapy is effective in delaying or preventing the onset of POAG in African American individuals who have ocular hypertension.